Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U02 Substudy 02B: Pembrolizumab Combinations in Advanced Melanoma
NCT04305054Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in melanoma (7 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicity at 3 weeks, Adverse Events at 28 months and 2 more. Started Jul 2020; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04305054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305054.